VolitionRX Ltd（VNRX）股票分析

AI 分析 of VolitionRX Ltd (VNRX)

持有

VolitionRX Ltd (VNRX) is currently trading at $0.1936, significantly below its 52-week high of $8.13, indicating potential for upside. However, the company has a troubling year-to-date change of -96.45% and a forward P/E ratio of 20.83, which suggests that while there is growth potential, it is not without risk. The recent partnership with Sysmex for optimizing diagnostic processes highlights a positive catalyst, but the company also reported a net income loss of -$7,326,047 in Q2 2026, which raises concerns about profitability. The RSI is at 52.60, indicating neutral momentum, and the stock is currently a penny stock, which adds to its volatility. The main risk is the high operating expenses that reached $6.3 million in Q1 2026, which could continue to pressure the company's financial health.

分析師評級（3）

上檔空間 +1062.19%

買進

3 買進

0 持有

0 賣出

目前: 0.19

最低

1.50

平均

2.25

最高

3.00

Maxim

買進

$4

2026-06-18

Maxim

2026-06-18

目標價

$4

買進

D. Boral Capital

持有

—

2026-04-20

D. Boral Capital

2026-04-20

目標價

—

持有

H.C. Wainwright

買進

$1

2026-04-02

H.C. Wainwright

2026-04-02

目標價

$1

買進

Maxim

持有

—

2025-12-03

Maxim

2025-12-03

目標價

—

持有

H.C. Wainwright

買進

—

2025-11-17

H.C. Wainwright

2025-11-17

目標價

—

買進

查看全部評級

估值指標

VolitionRX Ltd（VNRX）目前預期本益比為 20.83，5 年平均預期本益比為 -0.08。

預期本益比

嚴重高估

5 年均值 P/E

-0.08

目前P/E

20.83

高估

7.85

低估

-8.01

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-1.23

目前EV/EBITDA

-0.16

高估

0.22

低估

-2.67

預期股價營收比

合理

5 年均值 P/S

47.33

目前P/S

0.63

高估

136.80

低估

-42.14

Alphio AI 對 VNRX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%VNRX

$0.90

情境價格

基

基準

基準 · 50%VNRX

$0.83

情境價格

悲

悲觀

悲觀 · 25%VNRX

$0.80

情境價格

VNRX 常見問題 —— 由 Alphio AI 解答

VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

VolitionRX Ltd (VNRX) is currently trading at $0.1936, significantly below its 52-week high of $8.13, indicating potential for upside. However, the company has a troubling year-to-date change of -96.45% and a forward P/E ratio of 20.83, which suggests that while there is growth potential, it is not without risk. The recent partnership with Sysmex for optimizing diagnostic processes highlights a positive catalyst, but the company also reported a net income loss of -$7,326,047 in Q2 2026, which raises concerns about profitability. The RSI is at 52.60, indicating neutral momentum, and the stock is currently a penny stock, which adds to its volatility. The main risk is the high operating expenses that reached $6.3 million in Q1 2026, which could continue to pressure the company's financial health.

3 analysts cover VNRX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 2.25.